The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence (AI). In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Artificial intelligence in pharma: drug repurposing AI. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Drug repurposing AI is a key innovation area in artificial intelligence
AI-assisted drug repurposing involves utilizing artificial intelligence algorithms and techniques to identify potential new uses for existing drugs. This can involve analyzing large amounts of chemical and biological data to identify new molecular targets for these drugs, predicting the binding affinity of the drugs with the target, potential side effects and drug interactions, and identifying patient populations that may benefit from repurposed drugs.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 260+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of drug repurposing AI.
Key players in drug repurposing AI – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to drug repurposing AI
Source: GlobalData Patent Analytics
Ginkgo Bioworks is one of the leading patent filers in drug repurposing using AI. The company uses software and AI-based tools to engineer enzymes, proteins and drug molecules. A pioneer in digital health, the company combines computational design with synthetic biology platform and ultra-high-throughput genetic engineering and screening in process development and manufacturing scale-up.
In terms of application diversity, OncXerna Therapeutics leads the pack, while Memorial Sloan Kettering Cancer Center and Ginkgo Bioworks stood in the second and third positions, respectively. By means of geographic reach, Codexis held the top position, followed by Five3 Genomics and Worldwide Innovative Networking in personalized cancer medicine consortium.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Artificial Intelligence (AI) in Healthcare.